Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Targeting CYP51A1: small-Molecule inhibitors and therapeutic potential The cholesterol biosynthetic pathway has proven to be a successful target in drug development, as exemplified by statins for hypercholesterolemia and azole antifungals for infectious diseases [97, 98]
In the model, a time-limited programme generates a cumulative fiscal deficit of approximately CAD $12 billion by 2050
This framework converts raw patent data into the actionable financial intelligence that drives investment decisions whether that means upgrading a pharma stock that has underestimated its patent estate durability, downgrading one that has overclaimed its lifecycle management capability, or identifying a generic manufacturer with an underappreciated P.IV win probability
Bristol Myers Squibbs Eliquis, generating over $13 billion in 2024 revenue, with key patents expiring 2026-2028
US$ 28.60
US$ 25.97
US$ 27.28
US$ 29.41
US$ 20.87
US$ 28.89
US$ 23.62
US$ 23.71
US$ 21.52
US$ 23.53
